CIK 1008848LEI 5493007NPB5YRM8QGL53

Acorda Therapeutics, Inc.

EDGAR filings

Customers

None disclosed

Suppliers

0 disclosed

Latest period

Dec 31, 2018

10-K filed 2021-02-11

Suppliers 1

Companies that disclose Acorda Therapeutics, Inc. as a major customer, as a share of their own revenue. 0 active, 1 lapsed.

Company	% of their revenue	Est. $ from Acorda Therapeutics, Inc.	Period	Trend	Status	Source
ALKS Alkermes plc.	10%	$109.4M	FY 2018-12-31	−3.0pp	Lapsed Last seen 2018-12-31	10-K 2021-02-11
We receive certain commercial and development milestone payments, license revenues and a royalty of approximately 10% based on net selling price of AMPYRA and FAMPYRA by Acorda and its sub‑licensee, Biogen. 10-K filed 2021-02-11 Period FY 2018-01-01 to 2018-12-31 (10%)Accession 0001564590-21-005593 Acorda 15 % 10 % 14 % 13 % 17 % 15 % 10-K filed 2019-02-15 Period FY 2017-01-01 to 2017-12-31 (13%), FY 2016-01-01 to 2016-12-31 (15%)Accession 0001564590-19-003060 Acorda 14 % 13 % 17 % 15 % * 17 % 10-K filed 2018-02-16 Period FY 2015-01-01 to 2015-12-31 (17%)Accession 0001520262-18-000016 Acorda 17 % 15 % — % 17 % 17 % 13 % 10-K filed 2017-02-17 Period FY 2014-01-01 to 2014-12-31 (13%)Accession 0001520262-17-000007 Acorda 17 % 13 % 12 % 12 % 15 % 11 % 10-K filed 2015-02-24 Period FY 2012-04-01 to 2013-03-31Accession 0001047469-15-001083

Alerts are coming

Get an email when Acorda Therapeutics, Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.